Olink, part of Thermo Fisher’s Life Sciences Solutions and Verici Dx sign a certified service agreement and undertake cooperative marketing activities
Combining advanced proteomics technology with Verici’s technical laboratory skills and bioinformatics expertise within a CAP/CLIA/NYSDOH/ISO quality framework enhances biomarker discovery, validation, and application
FRANKLIN, Tenn., August 10, 2026 — Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics, with an accredited clinical laboratory offering integrated multi-omics services, today announced it has achieved status as an Olink Certified Service Provider. This designation allows Verici Dx to provide Olink-based proteomics assay services at its CAP certified/CLIA-accredited laboratory, supporting biomarker discovery, algorithm development, validation, and application in clinical trials and diagnostics internally and as a service.
In addition to analyzing samples from clients, Verici Dx will use the Olink platform to advance its own pipeline of protein biomarker-based development.
“Achieving Olink certification is an important milestone that reflects the strength of our laboratory team and our commitment to scientific excellence,” said Patti Connolly, Chief Operating Officer of Verici Dx. “What truly sets our laboratory apart, however, is the ability to go beyond sample processing. We bring together deep bioinformatics expertise and a CAP/CLIA/ISO quality system framework to support customers from biomarker discovery through product development and beyond.”
A Differentiated End-to-End Proteomics Offering
While many Olink service providers focus primarily on sample analysis, Verici Dx offers a fully integrated solution:
“Proteomics is a critical component of precision medicine and the broader multi-omics landscape,” said Connolly. “By integrating advanced proteomics with deep bioinformatics expertise, Verici Dx can help organizations generate more meaningful biological insights and translate complex data into clinically relevant applications.”
Demonstrated Impact in Clinical Research
Verici Dx has successfully applied its Olink-certified capabilities in a recent collaboration with a major pharmaceutical company evaluating samples from a GLP-1 clinical trial. The project leveraged a custom proteomic panel to evaluate biomarker responses in patient samples, with results contributing to ongoing scientific analyses and data submissions. This work demonstrates Verici Dx’s ability to execute complex, high-value projects with leading pharmaceutical and industry partners.
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company focused on supporting clinical management for improving outcomes in transplant patients. The company develops and commercializes advanced clinical laboratory assays by leveraging multi-omics approaches and proprietary machine learning derived algorithms to deliver actionable insights for improved patient management and clinical decision-making. Verici Dx’s lead product, Tutivia®, is a post-kidney transplant test focused on early risk assessment for acute rejection. Testing services are provided at the Company’s CAP certified/CLIA-accredited laboratory in Franklin, TN.
In addition to its transplant diagnostics portfolio, Verici Dx provides multi-omics services to support research, biomarker discovery, and algorithm development for external partners and to support internal initiatives. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.
Media Relations
Christine Quern
cq@christinequern.com
617-650-8497
